Rick Simpson Oil (RSO) in Anderson County: The Complete Guide

Understanding Rick Simpson Oil and What It Means for You

When people in Anderson County first hear about Rick Simpson Oil, they often have questions. What exactly is it? Is it legal? How is it different from regular CBD oil? We believe you deserve honest answers to all of these questions and many more. This guide represents our commitment to providing Anderson County with the most comprehensive, evidence-based education about RSO available anywhere.

The journey to understanding RSO begins with a man named Rick Simpson and takes us through decades of cannabis advocacy, scientific research, and product evolution. Today, modern formulated RSO products bear only a partial resemblance to what Simpson originally created. Understanding that evolution helps you make informed decisions about whether RSO might be right for your situation.

Who Is Rick Simpson and Why Does His Story Matter

The Origin of a Movement

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker whose path into cannabis advocacy began with personal suffering and a healthcare system that, in his experience, offered no adequate solutions.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. When he asked his physician to consider cannabis, the request was refused.

This experience of being let down by the medical system resonates with many people in Anderson County who have struggled with chronic conditions that conventional treatments have failed to address. Simpson’s story is not mythologized here—it is presented as his personal testimony, significant because it became the catalyst for a global movement.

The 2003 Experience That Changed Everything

Simpson reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days.

No independent medical verification of this outcome has been published. No biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed.

What Simpson did next defines his legacy. After his 2003 experience, he committed himself fully to producing and distributing concentrated cannabis oil. Operating from his property in Maccan, Nova Scotia, he began making oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped people with cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and many other conditions.

Run From The Cure and Global Awareness

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became foundational in cannabis communities worldwide—including reaching viewers in Texas who were searching for alternatives.

Legal Conflict and Exile

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support, he was raided again in 2009. Facing continued legal pressure, Simpson eventually left Canada for Europe, where he continued his advocacy from abroad.

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, detailing his experience, his oil-making process, and his broader philosophical views on cannabis and medicine. He maintained that cannabis oil could cure cancer and many other diseases, and that pharmaceutical companies and government agencies were actively suppressing this knowledge.

This framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant. Our responsibility is to present Simpson’s story honestly while providing the evidence-based assessment that follows.

What Traditional Rick Simpson Oil Actually Was

Understanding the Original Product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials.

Source Material: Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics. There was no strain standardization—the starting material varied by availability and growing season.

Extraction Solvent: Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. Neither naphtha nor isopropyl alcohol is a food-grade solvent. This is a significant safety concern.

Extraction Process: The traditional method involved placing cannabis plant material in a container, covering it with solvent, agitating to dissolve cannabinoids, filtering through cheesecloth, and evaporating the solvent using a rice cooker or similar heating device. The heat involved was sufficient to convert essentially all THCa into delta-9 THC—meaning traditional RSO was always a fully decarboxylated, psychoactive product.

Appearance: Traditional RSO was nearly black, thick, tar-like, with a strong cannabis odor and possible solvent-residual smell. The consistency was sticky and difficult to handle.

Cannabinoid Profile: Traditional RSO was THC-dominant, estimated at 60 to 90 percent THC by weight. Whatever minor cannabinoids the source strain contained were present at natural ratios, but these were never controlled, measured, or lab-verified.

Terpene Content: Minimal to none. The combination of solvent extraction and high-heat evaporation destroyed terpenes. This is a significant distinction from modern formulations.

Testing: None. Every batch was different. No Certificate of Analysis. No cannabinoid quantification. No contaminant screening.

Simpson’s Protocol

Simpson recommended a specific protocol: 60 grams of concentrated oil over approximately 90 days. The dosing escalation started at approximately half a grain of rice (10 to 15 milligrams) three times daily, doubling approximately every four days until reaching roughly 1 gram per day, divided into three doses.

This protocol was designed around crude, unstandardized material. At peak dosing, patients were consuming roughly 600 to 900 milligrams of delta-9 THC daily—far exceeding anything studied in controlled clinical settings. The FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day for comparison.

Safety Context

Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary treatment introduces risks that extend beyond the oil itself.

What Modern Science Actually Shows

The Evidence Framework

We prioritize evidence in this order: human clinical evidence, systematic reviews and meta-analyses, institutional summaries, then mechanistic or preclinical literature when human data are sparse. This hierarchy matters because the cannabinoid evidence base is not evenly distributed. Of the compounds in modern formulated RSO products, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes remain much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature.

What Institutions Say

The U.S. National Cancer Institute acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment. The FDA has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex for certain seizure disorders, and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting.

NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure.

What Preclinical Research Shows

In vitro studies have demonstrated that THC and CBD can induce apoptosis, inhibit proliferation, and reduce angiogenesis in certain cancer cell lines. Animal model studies have shown some tumor-growth inhibition. These findings have generated legitimate scientific interest and ongoing research.

However, these findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast and well-documented across all oncology research. No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.

What Simpson Got Right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness. The term RSO remains the most recognized name for full-spectrum cannabis extract in consumer vocabulary.

What Simpson Overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern.

How Modern RSO Evolved

The term RSO is now used broadly and often loosely across the legal cannabis industry. Many products labeled as RSO bear little resemblance to what Simpson originally made. In dispensaries today, RSO can refer to almost any full-spectrum cannabis extract sold in a syringe format, regardless of extraction method, cannabinoid profile, terpene content, or intended use.

Key Improvements in Modern Formulated RSO

Dimension	Traditional RSO	Modern Formulated RSO
Source material	Single high-THC indica strain	Multi-cannabinoid blend from multiple sources
Extraction method	Naphtha or isopropyl alcohol	Modern food-grade ethanol or CO₂ methods
Cannabinoid profile	THC-dominant, uncontrolled	Seven defined cannabinoids at specific ratios
Terpene content	Destroyed by high-heat process	Live terpenes preserved and added
Standardization	None—every batch different	Lab-tested with specific mg/mL targets
Lab testing	Not available or performed	Full panel testing with COAs
Residual solvents	Significant risk with naphtha	Controlled and tested
Dosing precision	Approximate, syringe-based	Measured per mL with known cannabinoid content
THCa preservation	No—fully decarboxylated by heat	Yes—THCa included as separate ingredient
Evidence approach	Anecdotal, personal testimony	Research-backed, evidence-weighted

Solvent Safety Evolution

Traditional RSO production used naphtha or isopropyl alcohol—neither of which is food-grade. Naphtha may contain benzene, toluene, and other compounds classified as toxic or carcinogenic. Incomplete solvent purging leaves potentially harmful residues in the finished oil.

Modern cannabis extraction uses food-grade ethanol or supercritical carbon dioxide. These methods allow for much more complete solvent removal, and finished products can be tested for residual solvents using validated analytical methods. This is one of the most straightforward improvements that the modern regulated cannabis industry has made over traditional production.

About OilWell Cannabis and Our RSO Formula

Our Origin Story

We founded OilWell Cannabis in Houston, Texas, but our story begins in the Rio Grande Valley. Colin Valencia grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, shaped his understanding of struggle, resilience, and what it means to fight for survival.

Colin’s childhood involved exposure to violence, loss, and hardship that most people cannot imagine. By sixteen, he had to leave home. But despite the dangers surrounding him, he did not fall into the darkest paths available. He chose cannabis instead—seeing it as a safer alternative that could actually help people. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in an industry that existed outside legal frameworks. Over time, he transitioned from those early ventures to creating a legitimate business in an industry he believes in.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—would eventually define our approach to formulation.

Bentley’s Story and the Foundation of Everything

Our company’s origin begins with a dog named Bentley. Bentley was more than a pet—he was family, a companion who stood by Colin through everything. When Bentley fell seriously ill, veterinarians delivered a devastating prognosis: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said pain medications would destroy his internal organs. The choice was between painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. Colin had already faced too much loss. In a desperate search for alternatives, he discovered the healing properties of CBD through a question that changed everything. A rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

Colin had cannabis experience—but it was recreational. Getting high. He had never explored therapeutic applications. Jessica’s question exposed a blind spot that would become a mission.

Determined to save Bentley, Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought his ball to play. From paralyzed and facing euthanasia to fetching his ball. Dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those years, Colin developed specialized cannabis formulas for every condition Bentley faced—neurodegeneration, dementia, glaucoma, crippling arthritis. Single cannabinoids were not enough. Minor cannabinoids like CBG, CBN, and CBC became critical as Bentley aged. Pharmaceutical precision mattered—Bentley’s life depended on it.

Bentley’s journey was Colin’s entry into cannabis beyond getting high. It became a mission to create real solutions that help alleviate pain and suffering, not just for pets but for people.

Colin’s Personal Experience with PTSD and Recovery

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—using the cannabinoid knowledge he had developed keeping Bentley alive. The Peace Gummies formula that became one of our products was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form of that formula to manage his insomnia and severe PTSD.

This is not theoretical knowledge. Colin lived what many of our customers live: desperation for relief, failed pharmaceuticals, the discovery that cannabinoids work when pills do not.

Our Houston Roots and Media Recognition

ABC13 Houston—the ABC affiliate serving America’s fourth-largest city—featured Colin and our company in seven comprehensive news segments spanning 2019 to 2023. Five different reporters sought Colin out across those years, covering Texas marijuana law, Delta-8 legal analysis, COVID-19 community health leadership, criminal justice reform, and cannabis business pioneering.

Colin has been repeatedly selected as the primary industry expert for cannabis policy and product coverage in Houston. From the earliest interview in September 2019, his philosophy has remained consistent:

“I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Today, we operate from Montrose in Houston at 810 Richmond Avenue. We have been operating since 2019, maintain a near-perfect Google rating, and are Texas DSHS licensed. All our artwork, formulations, and packaging are created in-house in Houston. We bring Houston grit, deep Texas roots, and a builder’s mindset to everything we do. Our posture stays simple: make products with intent, answer directly, and never pretend cannabis is right for everyone.

Our RSO Philosophy: Four Core Principles

1. Accessibility Over Gatekeeping

No medical card is required. Anyone age twenty-one or older can purchase. We ship nationwide across the United States and internationally to customers who verify local legality. Rick Simpson believed medicine should be accessible to everyone; we built a product and distribution model that makes that accessible legally.

For Anderson County residents, this matters. Texas has one of the most restrictive medical cannabis programs in the country—the Compassionate Use Program (TCUP) serves only patients with specific qualifying conditions. Our products are Farm Bill compliant and available without a medical card, delivered directly to your door.

2. Patient-Controlled Potency

THCa is sold in its acidic, non-psychoactive form. You decide whether to use it raw for non-psychoactive benefits or to decarboxylate it into delta-9 THC for full psychoactive potency. Rick Simpson believed patients should control their own medicine; we engineered a product that puts that control in your hands through chemistry rather than rhetoric.

This means the same product can function as a non-psychoactive anti-inflammatory during the day or as a full-potency therapeutic option at night—entirely based on your needs and preferences.

3. Open-Source Formulas

We publish our complete formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford our products can source ingredients and make their own version. Rick Simpson gave his oil away for free and taught people how to make it; we adapted that ethos for the modern cannabinoid marketplace by selling a professionally manufactured product and publishing the recipe.

This is not marketing. We published the CBD golden paste recipe that saved Bentley’s life years before we published our RSO formulas. The pattern is consistent—Colin gave away the formula that saved his dog before he gave away the formula designed for people.

4. Evidence-Informed, Not Evidence-Overstating

The science matters. We commit to honest education about what the research actually says. Rick Simpson operated without access to peer-reviewed literature or clinical trial data; we have that access, and we use it to distinguish between what is well-supported, what is emerging, and what is overstated.

Farm Bill Compliance and the THCa Legal Framework

The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC by dry weight at the federal level. This legal framework is the foundation of our RSO product design.

Our sublingual oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—3 milligrams per milliliter—well under the 0.3 percent threshold. All cannabinoids in the formula are hemp-derived. The product is legal under federal law and ships to Texas, including Anderson County, and most other states.

The Decarboxylation Choice Explained

THCa—tetrahydrocannabinolic acid—is the acidic, non-psychoactive precursor to delta-9 THC. It is not itself delta-9 THC. This distinction is legally significant: THCa is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC.

Three Usage Options:

Option 1 — Raw, no heat. All 1,500 milligrams of THCa stays as THCa—completely non-psychoactive. This provides the potential anti-inflammatory and neuroprotective benefits without any impairment. Compatible with work, driving, and daytime use.

Option 2 — Fully activated, home decarboxylation. Heating the oil at 260°F for 45 to 60 minutes in an oven-safe glass container converts THCa into delta-9 THC. Combined with the existing delta-9 THC and delta-8 THC in the formula, this creates a product with psychoactive potency comparable to traditional RSO—100 percent legally, because decarboxylation occurs at your discretion after purchase.

Option 3 — Vape, auto-decarboxylation. Our vape cartridge vaporizes at 400 to 450°F, which instantly converts THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset delivery method available.

Understanding the Evidence: Cannabinoids

CBD

Evidence profile: CBD has the strongest human evidence of any cannabinoid in our formula, especially when studied as a purified product.

What is best supported: Purified CBD has the most credible human evidence in seizure disorders—this is the clearest major indication acknowledged by institutional and peer-reviewed literature. A 2024 systematic review and meta-analysis covering 316 participants across eight studies reported a statistically significant anxiolytic signal for anxiety, though authors stressed that the clinical sample remains limited. A 2024 systematic review of CBD for pain found promising but heterogeneous results, with trial quality and consistency still limiting confidence. A 2023 insomnia review found that the sleep literature remains methodologically weak.

Safety considerations: CBD has been associated with liver enzyme elevation and possible drug-induced liver injury in some contexts, diarrhea, sleepiness, appetite changes, and drug-drug interactions. These considerations are especially relevant for concentrated oral products and anyone taking other medications.

What this means for our formula: At 4,500 mg in the sublingual formula, CBD provides the strongest evidence base of any compound in the product. It is not a generalized wellness ingredient—it has specific, research-supported applications.

CBG

Evidence profile: Mostly review-level and preclinical; human evidence remains sparse.

Pharmacology: CBG is the biosynthetic precursor to several major cannabinoids and appears pharmacologically distinct from both THC and CBD. Review literature describes interactions spanning cannabinoid receptors as well as alpha-2 adrenoceptors and 5-HT1A-related signaling.

Research areas: Published reviews discuss possible relevance to neurologic disorders, inflammatory bowel disease, and antibacterial activity, but these are primarily pharmacology-led hypotheses or preclinical findings rather than mature therapeutic conclusions.

Caution: CBG is already being sold commercially while the evidence base remains thin, which means claims frequently outrun the science.

What this means for our formula: At 3,000 mg, CBG is a serious research topic but should be described as a promising minor cannabinoid with limited clinical validation rather than as a proven therapeutic.

Delta-8 THC

Evidence profile: Pharmacologically relevant, psychoactive, and much less clinically characterized than delta-9 THC.

Comparative pharmacology: Delta-8 THC and delta-9 THC have broadly similar pharmacokinetic and pharmacodynamic behavior. Delta-8 THC is a partial CB1 agonist with cannabimimetic activity, but it appears less potent than delta-9 THC.

Public-health considerations: A 2023 scoping review found that much of the delta-8 evidence base is still dominated by animal studies, product chemistry, use reports, and public-health concerns rather than strong modern human trials. Manufacturing and product-quality concerns have been noted.

What this means for our formula: At 6,000 mg, delta-8 THC should be treated as a psychoactive cannabinoid with real pharmacologic activity and incomplete human safety characterization. It is not a “mild” or “minor” cannabinoid—it has meaningful potency.

THCa

Evidence profile: Important chemically and formulation-wise, but still low on direct human therapeutic evidence.

What it is: THCa is the acidic precursor of THC and may represent a very large share of THC-related content in raw plant material. The key formulation issue is that THCa decarboxylates into THC during heating and can also change during storage.

Psychoactivity: THCa itself does not produce psychoactive effects in humans, but the distinction only holds if the molecule stays in its acidic form and is not substantially decarboxylated.

Research status: In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, and antineoplastic possibilities, but these are not equivalent to established human outcomes.

What this means for our formula: At 1,500 mg, THCa is best understood as a highly relevant precursor molecule whose interpretation depends heavily on whether you use it raw or decarboxylated.

Delta-9 THC

Evidence profile: Strongest human evidence of the psychoactive cannabinoids, but also the clearest adverse-effect burden.

What is best supported: NCCIH identifies THC-containing cannabinoid medicines as relevant to chemotherapy-related nausea and vomiting, appetite and weight loss in HIV/AIDS, and some multiple-sclerosis and pain-related outcomes.

Pain evidence: Products with high THC content or roughly comparable THC:CBD ratios may provide short-term pain benefit, but they also increased dizziness, sedation, nausea, and treatment discontinuation due to adverse events in systematic reviews.

Mental-health risk: A 2025 systematic review found consistent unfavorable associations between high-concentration THC products and psychosis or schizophrenia outcomes, plus concerning signals for anxiety and depression in nontherapeutic settings.

What this means for our formula: At only 90 mg in the entire bottle (3 mg per mL), our delta-9 THC content is dramatically lower than traditional RSO formulations—providing therapeutic presence without the overwhelming psychoactive burden.

CBN

Evidence profile: Weak human evidence; marketing has clearly moved ahead of the data.

What it is often marketed for: Sleep and sedation. That reputation is widespread, but clinical support is far thinner than the market suggests.

Best direct review: A 2021 narrative review screened 99 human-study abstracts, reviewed eight full-text articles, and found no clinical trials using validated sleep questionnaires or formal polysomnography that could substantiate strong sleep-promoting claims for CBN alone.

What this means for our formula: At 750 mg, CBN is one of the clearest examples where cultural reputation is stronger than current clinical evidence. We include it because the emerging science is interesting, but we do not claim it is a proven sleep aid.

CBC

Evidence profile: Emerging, intriguing, and still overwhelmingly preclinical.

Pharmacology: A 2024 focused review argues that CBC has distinct pharmacodynamics, pharmacokinetics, and receptor behavior relative to better-known cannabinoids, highlighting antinociceptive, antibacterial, and anti-seizure areas as interesting research targets.

Safety caveat: Over-the-counter CBC products are already being sold despite little evidence establishing clinical efficacy or safety.

What this means for our formula: At 750 mg, CBC belongs in the category of scientifically credible minor cannabinoids that deserve more research, not the category of already-validated clinical actives.

Understanding the Evidence: Terpenes

Terpene claims need even stricter interpretation than cannabinoid claims. Much of the terpene literature comes from isolated compounds, essential oils, non-cannabis plants, or preclinical models rather than controlled human studies of cannabis formulations. Terpene bioactivity is plausible and sometimes compelling, but robust proof of clinically meaningful entourage effects in humans remains limited.

Our formula includes live terpenes at 5 percent with a defined seven-terpene profile:

Limonene

Largely review and preclinical evidence with useful safety literature. A 2021 review describes limonene as a multifunctional monoterpene with antioxidant, anti-inflammatory, and other possible activities, but most claims come from nonhuman or non-cannabis literature. Limonene oxidation products are clinically relevant contact allergens. Described as citrus-bright in aroma.

Myrcene

Mostly preclinical with very limited human evidence. A 2021 review describes anxiolytic, antioxidant, anti-inflammatory, and analgesic properties but explicitly states that human studies are lacking. Myrcene is often marketed as a proven sedating terpene—that claim is stronger than the evidence supports.

Beta-Caryophyllene

Among the most mechanistically interesting terpenes because of direct cannabinoid-system relevance. A 2021 focused review describes beta-caryophyllene as a selective CB2 receptor agonist—unusual and pharmacologically relevant. Anti-inflammatory, immunomodulatory, and neuroprotective actions are discussed in review literature, but human clinical confirmation remains limited. Described as pepper/spice in aroma.

Pinene

Promising preclinical literature, weak human clinical confirmation. A 2021 review on pinene and linalool as terpene-based medicines for brain health found antioxidant, anti-inflammatory, and neuroprotective signals that justify study, but emphasized that evidence is mostly preclinical. Claims about improving memory or counterbalancing THC-related cognitive effects remain interesting hypotheses. Described as forest-fresh in aroma.

Linalool

Substantial preclinical interest, limited direct clinical confirmation. Linalool is discussed in relation to stress, mood, and brain-health pharmacology. Oxidized linalool hydroperoxides are recognized allergens. Described as floral, lavender in aroma.

Humulene

Translationally interesting but still early. A 2024 scoping review found broad preclinical evidence for anti-inflammatory effects, with some rodent work suggesting cannabimimetic properties. Findings are valuable for hypothesis generation but do not establish human efficacy. Described as earthy, woody in aroma.

Terpinolene

One of the least clinically characterized terpenes. A 2021 systematic review concluded that terpinolene has a range of reported biological effects but that the evidence base is still dominated by in silico, in vitro, and animal studies. Described as piney, fruity, sparkling in aroma.

Our Products: Complete Formulas

RSO Sublingual Oil — $129.99

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5% (limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene)
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg
• Carrier: Organic MCT oil
• Dosing: Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent
• Approximate doses per bottle: 40 to 60 depending on serving size

RSO Vape Cartridge — $49.99

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%+
• Format: 1 gram cartridge
• Total cannabinoids: 900 mg+
• Battery compatibility: 510-thread universal
• Onset: 1 to 2 minutes (fastest cannabinoid delivery)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent (variable by inhalation technique)
• THCa: Automatic decarboxylation at vaping temperature (400 to 450°F)

When to Use Each Format

Use Case	Recommended Format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	Graduated dropper in 0.1 mL increments
Daytime non-psychoactive use	Sublingual (raw, no heat)	THCa stays inactive, zero impairment
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

Condition-Specific Usage Context

Important disclaimer: The following usage contexts are informed by cannabinoid research and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

Chemotherapy-Related Nausea and Appetite Support

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)
• Evidence context: delta-8 THC antiemetic evidence, delta-9 THC nausea and vomiting evidence, CBD anxiolytic buffering

Chronic Pain (Fibromyalgia, Arthritis, Neuropathy)

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset
• Evidence context: CBD pain evidence, delta-9 THC pain evidence, beta-caryophyllene CB2 agonism, THCa COX-2 inhibition

Sleep Support

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers approximately 50 mg CBN—the dosage level investigated in the sleep literature
• At 1.0 mL, this delivers approximately 25 mg CBN
• Evidence context: CBN sleep evidence, cannabis and sleep review literature

Anxiety and Stress

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety-related pathways without psychoactive impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture
• Evidence context: CBD anxiety evidence, CBG pharmacology, limonene entourage-effect evidence

General Titration Principle

Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

Common Questions from Anderson County Residents

Is This Legal in Texas?

Yes. Our products are Farm Bill compliant. The 2018 Farm Bill legalized hemp and hemp-derived products containing less than 0.3 percent delta-9 THC. Our sublingual oil contains only 90 mg of delta-9 THC in the entire 30 mL bottle—well under the legal limit. All cannabinoids are hemp-derived. We ship to Anderson County and throughout Texas.

Will I Get High?

It depends on how you use the product. The sublingual oil contains 1,500 mg of THCa in its non-psychoactive form. Used raw, it will not cause impairment—the THCa stays as THCa. If you choose to decarboxylate (heat) the oil, the THCa converts to delta-9 THC and the product becomes psychoactive. The vape cartridge auto-decarboxylates THCa with each inhalation, so it is always psychoactive.

Will This Show Up on a Drug Test?

Yes, it can. Delta-8 THC and activated THCa can trigger positive results for THC on standard drug tests. If you are subject to drug testing for employment, legal, or athletic reasons, you should not use products containing delta-8 THC or activated THCa without understanding this risk. The raw (non-decarbed) sublingual oil may be less likely to trigger positive results, but we cannot guarantee any outcome.

How Is This Different from Traditional RSO?

Traditional RSO used naphtha or isopropyl alcohol extraction, was always fully psychoactive, had no lab testing, and varied wildly in composition. Our products use food-grade ingredients and modern formulation methods, are lab-tested with certificates of analysis available, provide precise cannabinoid content, preserve THCa for patient-controlled potency, include seven cannabinoids rather than just THC, and include live terpenes that traditional RSO destroyed.

Do I Need a Medical Card?

No. Our products are Farm Bill compliant and require only age verification (21+). Texas has a limited medical cannabis program, but our products are available without participating in that program.

Ordering and Delivery for Anderson County

Nationwide Shipping

We ship to all 50 states where Farm Bill compliant products are legal, including Texas. Shipping options include USPS Priority Mail (2 to 3 business days), FedEx Ground, and UPS Ground. All packages are discreet with no cannabis branding visible. Tracking is provided for all orders. Temperature-stable packaging is used for summer shipments.

Houston Same-Day Delivery

For customers in the Houston area, we operate the only same-day RSO delivery system:

| Zone | Coverage | Delivery Fee |
|—|—|
| Texas Medical Center | All 60+ TMC institutions | FREE |
| Inner Loop (610) | Downtown, Midtown, Montrose, Heights, etc. | $5 |
| Within Beltway 8 | Bellaire, Memorial, Spring Branch, etc. | $10 |
| Greater Houston suburbs | Katy, Sugar Land, Pearland, Clear Lake, etc. | $15 |
| Extended region (60 miles) | Galveston, Baytown, Conroe, etc. | $20-25 |

Free delivery to the Texas Medical Center—the world’s largest medical complex with over 10 million patient visits annually—reflects our commitment to accessibility for patients who need it most.

International Shipping

We ship internationally and have already delivered to multiple countries across multiple continents. The THCa legal framework makes this possible: because the product contains less than 0.3 percent delta-9 THC at the point of sale, it meets the definition of a hemp-derived product under the Farm Bill and is shippable to jurisdictions with compatible hemp laws.

All international packages include full documentation, Certificates of Analysis, and receipts for customs purposes. Minimum flat-fee shipping applies; excessive international shipping costs are billed to the customer. The customer is responsible for verifying legality in their jurisdiction and accepts all customs and legal risk.

Contact Us

• Phone: (832) 416-2816
• Email: [email protected]
• Website: https://oilwellcbd.com/
• Instagram: @oilwellcbd
• Address: 810 Richmond Ave, Houston, TX 77006 (Montrose neighborhood)

Business Hours:

• Monday-Thursday: 10:00 AM – 7:00 PM
• Friday-Saturday: 10:00 AM – 10:00 PM
• Sunday: 10:00 AM – 4:00 PM

Our Broader Product Portfolio

Beyond RSO, we produce other cannabinoid products developed from the formulation knowledge Colin built over Bentley’s ten-year journey and his own experience with PTSD and benzo withdrawal:

Asshole Peach Gummy Rings — Our most popular product. Designed for euphoric, long-lasting effects. Particularly favored by veterans for pain and PTSD symptom relief. Contains delta-9 THC, delta-8 THC, delta-10 THC, THCo, CBD, and CBG.

Peace Gummy Peaches — Developed directly from Colin’s own experience with PTSD and benzodiazepine addiction. Helped him quit Xanax cold turkey. Also available in vape form for quick relief.

SWEETEMintz Sugar-Free Vegan Peppermint Hard Candy — Zero sugar, 100% vegan. Designed for diabetic and health-conscious consumers. Contains nano-enhanced delta-9 THC, CBD, and CBG isolate for rapid onset.

Custom Creations — We design tailored products on request for specific cannabinoid ratios, delivery formats, or health circumstances. This includes formulations for vegans, diabetics, and those with specific dietary needs.

A Note on Evidence and Integrity

Every cannabinoid in our formula—CBD, CBG, delta-8 THC, THCa, delta-9 THC, CBN, and CBC—has its own evidence profile documented in this guide. We do not claim therapeutic outcomes that the evidence does not support. We do not promise cures. We do not overstate what the science shows.

Colin said it best in our first ABC13 interview in 2019:

“I’m not trying to sell people snake oil. I’m not trying to sell people hope. But there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

That philosophy guides everything we do. The formulas in this document are anchored to per-compound evidence summaries that explain what is well-supported, what is emerging, and what is overstated. We publish those summaries because you deserve to know what the science actually says—not just what marketing claims.

For Our Neighbors in Anderson County

We know that many of you in Anderson County are searching for alternatives. Maybe you’ve tried conventional treatments that didn’t work. Maybe you’re dealing with chronic pain, cancer treatment side effects, PTSD, insomnia, or anxiety that pharmaceuticals haven’t adequately addressed. Maybe you’re a caregiver looking for options for someone you love.

We built this company because we lived those experiences ourselves. Colin lived them—through Bentley’s decade of health challenges, through his own PTSD and benzo withdrawal, through years of formulating and testing and learning what actually works. We’re not a corporate brand that saw a market opportunity. We’re people who discovered cannabinoid medicine out of necessity and decided to make it accessible to others.

Anderson County is a community that understands resilience. The people there know what it means to fight for family, for health, for the chance at a better life. We respect that. Our commitment to Anderson County is the same commitment we make to every customer: honest education, transparent formulas, products made with intent, and the refusal to pretend cannabis is right for everyone.

If you’re reading this guide, you’re taking the time to educate yourself before making decisions. That’s exactly what we believe everyone should do. We’re here to answer your questions honestly, ship you products that meet the specifications we’ve published, and stand behind what we make.

We don’t know if our products are right for you. Only you and your healthcare provider can make that determination. But we do know that you deserve the best possible version of the information—the same version we use ourselves.

References

The full reference list for this guide includes 29 peer-reviewed citations across multiple journals and institutional sources, covering:

• NCCIH official guidance on cannabis and cannabinoids
• Clinical evidence for CBD in seizure disorders, anxiety, pain, and insomnia
• Pharmacology and safety profiles for all seven cannabinoids in our formulas
• Terpene research including reviews on limonene, myrcene, caryophyllene, pinene, linalool, humulene, and terpinolene
• Systematic reviews on cannabis for chronic pain, sleep, and mental health outcomes
• Research on THCa, delta-8 THC, CBG, CBN, and CBC
• Entourage effect literature

We provide these citations not to overwhelm but to demonstrate that every claim we make about compounds is sourced from the actual scientific literature—not from blogs, influencers, or manufacturer marketing. If you want to read the original research, we’re happy to point you toward the specific studies that inform each section of this guide.

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids. Keep out of reach of children. Buyer is responsible for verifying legality in their jurisdiction.